ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene

Patent metadata

Field	Value
Publication number	US-11780925-B2
Application number	US-201816499185-A
Country	US
Kind code	B2
Filing date	Apr 3, 2018
Priority date	Mar 31, 2017
Publication date	Oct 10, 2023
Grant date	Oct 10, 2023

Abstract

The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.

First claim

The invention claimed is:

1. A method of treating a cancer in a subject, wherein the cancer comprises an ErbB-2 and ErbB-3 positive cancer cell, the method comprising administering a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2, and a second antigen-binding site that can bind an extracellular part of ErbB-3 to the subject, wherein the cell comprises an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location;
the first antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:42;
the second antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:55, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:56; and
wherein the first antigen binding site and the second antigen binding site comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 comprising the amino acid sequence SEQ ID NO:77.

2. The method of claim 1 , wherein the NRG1 fusion gene comprises at least the 3′ end of the NRG1 gene fused to a 5′ sequence from a different chromosomal location.

3. The method of claim 1 , wherein the cell is a breast cancer cell, an ovarian cancer cell, a lung cancer cell, a non-small cell lung cancer, or a metastasis thereof.

4. A method of treating cancer in a subject, wherein the cancer comprises an ErbB-2 and ErbB-3 positive tumor, the method comprising administering a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2 and a second antigen-binding site that can bind an extracellular part of ErbB-3 to the subject, wherein one or more cells of the cancer express an NRG1 fusion gene comprising at least the 3′ end of the NRG1 gene fused to a 5′ sequence from a different chromosomal location; wherein
the first antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:42;
the second antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:55, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:56; and
wherein the first antigen binding site and the second antigen binding site comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 comprising the amino acid sequence SEQ ID NO:77.

5. The method of claim 4 , wherein the tumor is a breast tumor, an ovarian tumor, a lung tumor, a non-small cell lung tumor, or a metastasis thereof.

6. The method of claim 4 , wherein the NRG1-fusion gene expresses a protein that comprises an NRG1 EGF-like domain.

7. The method of claim 6 , wherein the NRG-fusion is a fusion of NRG1 and a gene on human chromosome 8.

8. The method of claim 7 , wherein the gene on human chromosome 8 encodes an excreted protein or a cellular membrane associated protein.

9. The method of claim 4 , wherein the NRG1 fusion gene is a fusion of the 3′ end of the NRG1-gene with the 5′ sequence of one of the genes selected from the group consisting of CD74; DOC4; TNFRSF10B; CLU; VAMP2; SLC3A2; RBPMS; WRN; SDC4; KIF13B; SLECA2; PDE7A; ATP1B1; CDK1; BMPR1B; MCPH1; and RAB2IL1.

10. The method of claim 4 , wherein the cell or tumor is of an epithelial origin.

11. The method of claim 4 , wherein the individual has undergone a therapy targeted towards EGFR inhibition.

12. The method of claim 4 , wherein a ErbB-1 cell-surface receptor density; a ErbB-2 cell-surface receptor density; a ErbB-3 cell-surface receptor density; a ErbB-4 cell-surface receptor density, or a combination thereof on cells of the tumor has been determined.

13. The method of claim 12 , wherein the tumor has less than 400,000 ErbB-1 cell-surface receptors per cell or less than 200,000 ErbB-1 cell-surface receptors per cell.

14. The method of claim 4 , further comprising administering to the individual an ErbB-1 inhibitor.

15. The method of claim 14 , wherein the ErbB-1 inhibitor is cetuximab.

Assignees

• Merus Nv

Inventors

• Throsby Mark
• Geuijen Cecilia Anna Wilhelmina
• Maussang-Detaille David Andre Baptiste
• Logtenberg Ton

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/32 Primary

  against translation products of oncogenes · CPC title

• C07K16/2863 Primary

  against receptors for growth factors, growth regulators · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title